Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03896737
Title Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Myeloma Network
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA | GRC | CZE


No variant requirements are available.